Ifosfamide in the treatment of non-small cell lung cancer.
Ifosfamide in the treatment of non-small cell lung cancer.
复制标题
异环磷酰胺治疗非小细胞肺癌。
作者：
D. Ettinger
应用异环磷酰胺对1326例可评价的非小细胞肺癌患者进行了13种单药和23种联合化疗方案的临床研究。从这些研究中可以得出几个结论：(1)异环磷酰胺作为单一药物的有效率超过20%；(2)异环磷酰胺与顺铂联合使用时，无论是否有第三种药物，异环磷酰胺的有效率为38%；但生存率并没有显著增加；(3)异环磷酰胺与其他有效药物的联合有效率超过35%；(4)异环磷酰胺需要与其他有效药物联合进行持续的评估和测试。
Thirteen single-agent and 23 combination chemotherapeutic regimen trials using ifosfamide involving 1,326 evaluable patients with non-small cell lung cancer were reviewed. From these studies, several conclusions can be drawn: (1) ifosfamide as a single agent shows response rates greater than 20%; (2) in combination with cisplatin, with or without a third drug, ifosfamide induces response rates of 38%; however, survival is not increased significantly; (3) other combinations with ifosfamide have a response rate greater than 35%; and (4) ifosfamide warrants continued evaluation and testing in combination with other effective agents.